Autoimmune gastritis Medical Services in China

Autoimmune gastritis (AIG) is a chronic, immune-mediated inflammatory disorder characterized by the progressive destruction of gastric parietal cells and intrinsic factor–producing chief cells in the gastric corpus and fundus. This leads to achlorhydria (absent or severely reduced gastric acid secretion), hypergastrinemia, and impaired vitamin B12 absorption—ultimately resulting in pernicious anemia if untreated. Pathogenesis centers on loss of immune tolerance: autoreactive CD4+ T lymphocytes infiltrate the gastric mucosa, triggering antibody production against parietal cell H+/K+ ATPase (the proton pump) and intrinsic factor. These autoantibodies—particularly anti–H+/K+ ATPase antibodies—are highly specific (>90%) for AIG and serve as key diagnostic biomarkers. Complement activation and cytokine-driven mucosal atrophy further perpetuate glandular loss, metaplasia (often intestinal), and increased risk of gastric neuroendocrine tumors (type I carcinoids) and gastric adenocarcinoma. Epidemiologically, AIG affects approximately 0.5–2% of the general population, with prevalence rising sharply with age—reaching 2–5% in adults over 60 years. It is significantly more common in women (F:M ≈ 3:1) and strongly associated with other autoimmune conditions, including Hashimoto’s thyroiditis (30–50% co-occurrence), type 1 diabetes mellitus (5–10%), vitiligo, and Addison’s disease. Genetic susceptibility involves HLA-DRB1*03:01 and HLA-DQB1*02:01 alleles. Environmental triggers remain poorly defined but may include molecular mimicry following viral or bacterial infections (e.g., Helicobacter pylori—though AIG is typically H. pylori-negative, prior infection may modulate immune responses). Risk factors include female sex, age >50 years, personal or family history of autoimmunity, and certain genetic polymorphisms in immune-regulatory genes (e.g., CTLA-4, PTPN22). Clinically, AIG is often insidious and asymptomatic in early stages; when symptoms emerge, they are frequently nonspecific—fatigue, pallor, dyspnea on exertion (due to B12-deficiency anemia), glossitis, paresthesias, or mild epigastric discomfort. Importantly, patients rarely report classic dyspepsia or reflux, distinguishing AIG from functional dyspepsia or H. pylori gastritis. Quality of life impact is substantial but underrecognized: chronic fatigue and cognitive fog from B12 deficiency impair work performance and daily functioning; neurological complications (subacute combined degeneration) may become irreversible without timely intervention; psychological burden includes anxiety about cancer risk and lifelong dependency on injectable or high-dose oral B12 replacement. Long-term surveillance via endoscopy with targeted biopsies is recommended every 3–5 years in patients with extensive atrophy or intestinal metaplasia to detect dysplasia or early neoplasia. Patient education, multidisciplinary care (gastroenterology, hematology, endocrinology), and proactive monitoring are essential to mitigate morbidity and preserve quality of life.

Autoimmune gastritis (AIG) is a chronic, immune-mediated inflammatory disorder characterized by the destruction of gastric parietal cells and intrinsic factor–producing chief cells in the gastric corpus and fundus. This leads to achlorhydria, hypergastrinemia, and ultimately vitamin B12 deficiency due to impaired intrinsic factor synthesis and subsequent malabsorption. The primary cause is loss of immunologic tolerance to gastric autoantigens—most notably the H+/K+ ATPase proton pump expressed on parietal cell membranes. Circulating autoantibodies against this enzyme are highly specific (>90%) for AIG and serve as a key serologic biomarker. These antibodies, along with autoreactive CD4+ T lymphocytes, drive a Th1- and Th17-polarized mucosal immune response, resulting in progressive atrophy of oxyntic glands, metaplastic transformation (e.g., pseudopyloric or intestinal metaplasia), and glandular loss.

Triggers of disease onset remain incompletely defined but likely involve antigenic mimicry, molecular mimicry between microbial epitopes and gastric H+/K+ ATPase subunits, or aberrant presentation of self-antigens following mucosal injury. Viral infections—including Epstein-Barr virus (EBV) and cytomegalovirus (CMV)—have been implicated in case reports as potential precipitants, possibly via bystander activation or epitope spreading. Chronic Helicobacter pylori infection is not a direct cause of AIG; however, its eradication in susceptible individuals may unmask or accelerate preexisting autoimmune gastritis by removing competitive immune regulation or altering the gastric microbiome and local cytokine milieu. Stress-induced mucosal barrier disruption and prolonged use of proton pump inhibitors (PPIs), which induce hypergastrinemia and parietal cell hypertrophy, may theoretically promote antigen exposure and immune sensitization—though robust epidemiologic evidence linking PPIs to AIG initiation is lacking.

Established risk factors include female sex (female-to-male ratio ~3:1), advancing age (peak incidence 50–70 years), and coexistence of other organ-specific autoimmune disorders. Up to 30–40% of patients with AIG have concomitant autoimmune thyroid disease (Hashimoto’s thyroiditis or Graves’ disease), 15–25% have type 1 diabetes mellitus, and smaller proportions exhibit autoimmune adrenal insufficiency (Addison’s disease), vitiligo, alopecia areata, or primary ovarian insufficiency. This clustering reflects shared underlying immune dysregulation rather than direct causation.

Genetic susceptibility is strongly associated with human leukocyte antigen (HLA) class II alleles, particularly HLA-DQA1*05:01 and HLA-DQB1*02:01 (forming the DQ2.5 heterodimer), which are also linked to celiac disease and type 1 diabetes. Polymorphisms in non-HLA immune regulatory genes—including CTLA-4 (cytotoxic T-lymphocyte–associated protein 4), PTPN22 (protein tyrosine phosphatase non-receptor type 22), and IL2RA (interleukin-2 receptor alpha chain)—further modulate T-cell activation thresholds and contribute to loss of peripheral tolerance. First-degree relatives of AIG patients demonstrate increased prevalence of gastric autoantibodies and subclinical atrophy, supporting heritable predisposition.

Environmental factors play a permissive or modifying role. Smoking appears protective in some cohort studies—possibly via nicotine-mediated immunomodulation—but findings are inconsistent and confounded by behavioral variables. Dietary iodine excess may exacerbate concurrent autoimmune thyroiditis, indirectly influencing AIG clinical expression. Early-life exposures—including cesarean delivery, antibiotic use in infancy, and reduced microbial diversity—may impair thymic education and regulatory T-cell development, thereby increasing lifetime autoimmune risk. Vitamin D deficiency has been associated with higher titers of gastric autoantibodies and more severe histologic atrophy, suggesting a potential immunoregulatory role. Conversely, chronic NSAID use and alcohol consumption are not established risk factors for AIG, distinguishing it from environmental or reactive gastritides. Importantly, AIG is not associated with socioeconomic status, geographic region, or dietary habits such as spicy food intake. Surveillance for gastric neuroendocrine tumors (type I carcinoids) and gastric adenocarcinoma is warranted given the neoplastic potential of long-standing atrophic gastritis and intestinal metaplasia.

Autoimmune gastritis (AIG) is a chronic, immune-mediated inflammatory disorder characterized by T-lymphocyte infiltration of the gastric corpus and fundus, leading to progressive atrophy of parietal and chief cells, achlorhydria, and intrinsic factor deficiency. It predominantly affects middle-aged to older adults, with a strong female predominance (F:M ratio ~3–4:1), and is frequently associated with other organ-specific autoimmune conditions such as Hashimoto thyroiditis, type 1 diabetes mellitus, vitiligo, and Addison disease. Unlike Helicobacter pylori–induced gastritis, AIG spares the antrum and is not associated with significant dyspeptic symptoms in its early phase—making it a largely silent, insidious disease.

Early symptoms are typically absent or nonspecific. Up to 70% of patients remain asymptomatic for years despite advanced histologic atrophy and functional impairment. When present, early manifestations may include mild, intermittent epigastric discomfort, subtle postprandial fullness, or vague abdominal bloating—none of which are reliably distinguishable from functional dyspepsia or mild reflux. Importantly, classic dyspeptic features such as burning pain, acid regurgitation, or nausea are notably uncommon and should prompt reconsideration of alternative diagnoses. Some patients report mild fatigue or unexplained lassitude, often dismissed as age-related or stress-induced; however, these may reflect subclinical iron deficiency or early vitamin B12 depletion.

Typical symptoms emerge only after substantial glandular destruction and functional decompensation—usually after a decade or more of subclinical disease. The hallmark clinical presentation is that of megaloblastic anemia secondary to vitamin B12 deficiency: progressive fatigue, exertional dyspnea, palpitations, pallor, and occasionally mild jaundice due to ineffective erythropoiesis and hemolysis. Neurologic manifestations—including distal paresthesias, impaired vibration and proprioception (posterior column involvement), gait ataxia, and, in advanced cases, cognitive slowing or mild dementia—may develop insidiously and are often irreversible if diagnosis is delayed. Iron deficiency anemia may coexist, particularly in premenopausal women or individuals with concomitant celiac disease, manifesting as brittle nails, koilonychia, glossitis, or restless legs syndrome. Notably, upper gastrointestinal endoscopy is usually normal or reveals only subtle findings—such as loss of rugal folds, mucosal pallor, or fine granularity—rendering endoscopic suspicion low without high clinical index.

Accompanying symptoms reflect systemic autoimmune comorbidity and endocrine sequelae. Patients frequently report symptoms of hypothyroidism (cold intolerance, constipation, dry skin, weight gain) or hyperthyroidism (if coexisting Graves disease). Hypoglycemic episodes may occur in those with latent autoimmune diabetes of adulthood (LADA). Rarely, patients describe episodic diarrhea or steatorrhea, attributable to concomitant autoimmune enteropathy or exocrine pancreatic insufficiency. Autoimmune hepatitis or primary biliary cholangitis may contribute to pruritus or right upper quadrant discomfort. Importantly, achlorhydria predisposes to bacterial overgrowth (e.g., Enterococcus, Klebsiella), potentially causing subacute malabsorption, bloating, and diarrhea—though overt infectious gastroenteritis is uncommon.

Complications arise from chronic atrophy and hormonal deficiencies. The most consequential is pernicious anemia, defined by B12 deficiency due to intrinsic factor autoantibodies and gastric atrophy. Untreated, it leads to irreversible subacute combined degeneration of the spinal cord. Gastric neuroendocrine tumors (type 1 gastric carcinoids) develop in ~2–8% of patients due to chronic hypergastrinemia-driven enterochromaffin-like (ECL) cell hyperplasia; these are typically small (<1 cm), multifocal, and indolent but require surveillance via endoscopy with biopsies every 2–3 years. Gastric adenocarcinoma risk is modestly elevated (relative risk ~2–3×), particularly in patients with extensive intestinal metaplasia or dysplasia, though absolute incidence remains low. Iron, folate, calcium, and vitamin D malabsorption may contribute to osteopenia or osteoporosis. Hypochlorhydria also impairs absorption of medications (e.g., levothyroxine, bisphosphonates) and increases susceptibility to enteric infections (e.g., Salmonella, Campylobacter).

Diagnosis relies on a multimodal approach. Serum biomarkers form the cornerstone: elevated fasting serum gastrin (>1000 pg/mL in context of achlorhydria), low or undetectable pepsinogen I, and a low pepsinogen I/II ratio (<3.0) indicate corpus-predominant atrophy. Anti–parietal cell antibodies (APCA) are present in ~80–90% of cases but lack specificity (also positive in 10–15% of healthy elderly and in other autoimmune diseases). Anti–intrinsic factor antibodies (AIFA) are highly specific (>95%) but less sensitive (~50–70%). Serum vitamin B12 <200 pg/mL (with confirmatory methylmalonic acid >0.4 µmol/L and homocysteine >15 µmol/L) supports functional deficiency. Endoscopic biopsy remains gold standard: histology shows lymphoplasmacytic infiltration, oxyntic gland atrophy, pseudopyloric metaplasia, and absence of H. pylori. Biopsies must be taken from the corpus (not antrum) and assessed using the updated Sydney System with OLGA/OLGIM staging. Chromoendoscopy with acetic acid or methylene blue enhances detection of atrophic margins.

Differential diagnosis is critical to avoid misattribution. Functional dyspepsia lacks biomarker abnormalities and histologic atrophy. H. pylori gastritis involves the antrum, shows active neutrophilic inflammation, and demonstrates organism on staining or PCR. Drug-induced gastritis (e.g., NSAIDs, bisphosphonates) presents with acute erosions or ulcers rather than atrophy. Lymphocytic gastritis exhibits intraepithelial lymphocytes (>25/100 epithelial cells) and is often linked to celiac disease. Crohn disease may involve stomach but shows transmural inflammation, noncaseating granulomas, and skip lesions. Eosinophilic gastritis features prominent eosinophilic infiltration and peripheral eosinophilia. Zollinger–Ellison syndrome causes hypergastrinemia but with gastric hypersecretion (not achlorhydria), peptic ulcer disease, and gastrinoma on imaging. Finally, gastric lymphoma (MALT) may mimic AIG clinically but demonstrates monoclonal B-cell expansion on flow cytometry or molecular studies. Accurate distinction hinges on integrating serology, histopathology, endoscopic topography, and exclusion of confounding factors including recent PPI use (which elevates gastrin and masks achlorhydria).

Autoimmune gastritis (AIG) is a chronic, immune-mediated inflammatory disorder characterized by T-lymphocyte infiltration of the gastric corpus and fundus, leading to progressive atrophy of parietal and chief cells, achlorhydria, and intrinsic factor deficiency. This results in impaired vitamin B12 absorption and subsequent pernicious anemia, as well as elevated serum gastrin levels due to loss of acid feedback inhibition. AIG is strongly associated with other autoimmune conditions—including Hashimoto’s thyroiditis, type 1 diabetes mellitus, and vitiligo—and carries an increased risk of gastric neuroendocrine tumors (type 1 gastric carcinoids) and gastric adenocarcinoma, albeit at low absolute incidence. Management focuses on lifelong surveillance, nutritional repletion, and complication prevention rather than disease modification, as no therapy currently halts or reverses the underlying autoimmune destruction.

Conservative treatment forms the cornerstone of AIG management and emphasizes regular monitoring and lifestyle adaptation. Patients require lifelong endoscopic surveillance—typically every 3–5 years—to detect dysplasia, early neoplasia, or type 1 gastric carcinoids, especially in those with persistent hypergastrinemia (>1000 pg/mL), extensive atrophy, or intestinal metaplasia. Upper gastrointestinal endoscopy with high-definition white-light imaging and targeted biopsies (per Sydney System protocol: antrum, incisura, corpus, and fundus) is mandatory for baseline staging and longitudinal assessment. Serum biomarkers—including fasting gastrin, pepsinogen I, pepsinogen II, and the pepsinogen I/II ratio—are monitored annually to track gastric atrophy progression. Nutritional counseling is integral: patients must avoid proton pump inhibitors (PPIs) unless absolutely indicated (e.g., concomitant GERD), as exogenous acid suppression exacerbates hypergastrinemia and may theoretically promote enterochromaffin-like (ECL) cell hyperplasia. Dietary modifications include small, frequent meals rich in bioavailable iron (heme iron from lean meats), folate (leafy greens, legumes), and calcium/vitamin D to mitigate osteoporosis risk secondary to chronic achlorhydria and potential malabsorption.

Pharmacotherapy in AIG is entirely supportive and symptom- or deficiency-driven. Vitamin B12 replacement is non-negotiable for all patients with documented deficiency (serum B12 <200 pg/mL) or functional deficiency (elevated methylmalonic acid or homocysteine). Intramuscular cyanocobalamin (1000 µg monthly after initial loading doses) remains first-line; however, high-dose oral B12 (1000–2000 µg daily) is equally effective in most cases and preferred for long-term adherence, given its safety and lack of need for injections. Iron supplementation (ferrous sulfate 325 mg 1–3× daily, with vitamin C to enhance absorption) is initiated for iron-deficiency anemia, often requiring 3–6 months of therapy followed by maintenance dosing if ongoing losses or malabsorption persist. Folate supplementation (1–5 mg daily) may be added in cases of megaloblastic anemia unresponsive to B12 alone. Notably, immunosuppressive agents—including corticosteroids, azathioprine, or biologics—have no proven efficacy in AIG and are contraindicated due to lack of benefit and significant infection/malignancy risks. PPIs should be used sparingly and only under gastroenterologist supervision, with strict documentation of indication and periodic reassessment.

Surgical intervention has no role in the primary management of AIG. Gastrectomy or antrectomy is neither indicated nor beneficial for controlling autoimmunity or preventing complications. However, surgery becomes necessary in rare, advanced scenarios: endoscopically unresectable type 1 gastric carcinoids (>1 cm, multifocal, or with invasion beyond the lamina propria) may require endoscopic mucosal resection (EMR) or, less commonly, laparoscopic wedge resection or distal gastrectomy. Similarly, high-grade dysplasia or early gastric adenocarcinoma mandates oncologic resection per Japanese Gastric Cancer Association (JGCA) or NCCN guidelines. These procedures are performed exclusively by specialized upper GI surgeons in high-volume centers and are not curative for AIG itself but address discrete malignant complications.

Treatment advantages in China stem from integrated, multidisciplinary infrastructure and policy-driven accessibility. First, China’s national gastric cancer screening program—implemented in high-risk regions since 2012—provides standardized, subsidized endoscopy and histopathology for individuals with chronic atrophic gastritis, enabling earlier AIG detection and risk stratification. Second, Chinese tertiary hospitals (e.g., Peking Union Medical College Hospital, Zhongshan Hospital Fudan University) host dedicated Autoimmune GI Clinics where gastroenterologists, endocrinologists, hematologists, and nutritionists collaborate on longitudinal care, including rapid turnaround for serum gastrin/pepsinogen assays (<48 hours) and digital pathology review. Third, China manufactures high-quality generic formulations of cyanocobalamin, ferrous fumarate, and folate at <10% the cost of branded equivalents in Western markets, ensuring affordability for lifelong supplementation. Fourth, AI-assisted endoscopic systems (e.g., EndoBRAIN, developed by Olympus and Shanghai Jiao Tong University) improve detection sensitivity for subtle ECL hyperplasia and microcarcinoids during surveillance, reducing interobserver variability. Finally, China’s National Health Commission mandates electronic health record integration across provinces, facilitating seamless tracking of B12 levels, endoscopy intervals, and biopsy results—critical for preventing gaps in chronic disease management.

Recovery and long-term prognosis hinge on strict adherence to surveillance and supplementation—not ‘cure,’ as AIG is irreversible. Patients should undergo annual complete blood count, serum B12, ferritin, folate, and vitamin D testing; repeat upper endoscopy per risk-stratified intervals (every 3 years for severe atrophy/hypergastrinemia; every 5 years for mild-moderate disease). Smoking cessation and alcohol abstinence are strongly advised, as both accelerate gastric mucosal damage. Patients must be counseled that fatigue, glossitis, or neuropathy signal possible B12 inadequacy—even with supplementation—and warrant immediate evaluation. Pregnancy requires intensified monitoring: B12 doses may increase to 1000 µg twice weekly, and fetal neural tube defect risk necessitates concurrent high-dose folate (4–5 mg/day) preconception through the first trimester. With consistent care, life expectancy is normal; however, 10–15% develop gastric carcinoids over 20 years, and 1–3% progress to adenocarcinoma—underscoring that vigilance, not passivity, defines successful recovery. Ultimately, AIG management epitomizes preventive gastroenterology: proactive, personalized, and perpetually vigilant.